topotecan


Also found in: Wikipedia.

topotecan

/to·po·te·can/ (to″po-te´kan) an antineoplastic that inhibits DNA topoismerase; used as the hydrochloride salt in the treatment of metastatic ovarian carcinoma and small cell lung carcinoma.

topotecan

an antineoplastic hormone.
indication It is used to treat metastatic carcinoma of the ovary after failure of traditional chemotherapy.
contraindications Factors that prohibit the use of this drug are known hypersensitivity, lactation, and severe bone marrow depression.
adverse effects Life-threatening effects are neutropenia, leukopenia, thrombocytopenia, anemia, and sepsis. Other adverse effects are abdominal pain, constipation, diarrhea, obstruction, nausea, stomatitis, vomiting, increased alanine aminotransferase and aspartate aminotransferase, anorexia, arthralgia, asthenia, headache, myalgia, pain, dyspnea, and total alopecia.

topotecan

A water-soluble derivative of camptothecin, obtained from the Chinese tree Camptotheca accuminata. It is a topoisomerase inhibitor which is FDA-approved for treating ovarian, cervical and small cell carcinoma of the lung.

topotecan

Hycamtin® Oncology A topoisomerase I inhibitor used for refractory ovarian CA, small cell CA, and for colorectal and breast CAs Adverse effects Dose-limiting–never if baseline neutrophils are < 1500 cells/mm3–neutropenia, anemia, thrombocytopenia; N&V, diarrhea, alopecia Contraindications Pregnancy, breastfeeding, prior BM depression. See Topoisomerase I.

topotecan

The first of the CAMPOTHECIN analogue drugs to be approved for clinical use. Topotecan is a TOPOISOMERASE inhibitor drug used to treat cancer of the ovary and small cell cancer of the lung. (see CYTOTOXIC DRUGS). A brand name is Hycamtin.
References in periodicals archive ?
Additionally, it is approved in combination with interferon alfa-2a for advanced and/or metastatic renal cell cancer; in combination with carboplatin and paclitaxel, carboplatin and gemcitabine, and paclitaxel, topotecan, or pegylated liposomal doxorubicin for advanced, platinum-sensitive, or platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and in combination with paclitaxel and cisplatin, or alternatively, paclitaxel and topotecan for persistent, recurrent, or metastatic carcinoma of the cervix.
It was also recommended as a treatment in combination with erlotinib for unresectable advanced, metastatic or recurrent non-squamous NSCLC; in combination with interferon alfa-2a for advanced and/or metastatic renal cell cancer; in combination with carboplatin and paclitaxel, carboplatin and gemcitabine, and paclitaxel, topotecan, or pegylated liposomal doxorubicin for advanced, platinum-sensitive, or platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer;
We further showed that MHP-1 restored sensitivity in topotecan (TPT)-resistant MCF-7 cells that developed an EMT-like phenotype.
Two clinically used CPT derivatives irinotecan (CPT-11) and topotecan are widely used to inhibit the growth of lung cancer in combination with cisplatin, paclitaxel [9], and bevacizumab [10].
Topotecan (1 mg) and carboplatin (30-50 mg) are alternative chemotherapeutic agents.
Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's Oncology Group study D9803.
During the trial, patients were randomised to one of six treatment units (paclitaxel, topotecan or pegylated liposomal doxorubicin with or without Avastin).
Topotecan inhibited ovarian cancer-initiating cells (CP70 SPS) in vitro more than it did their parental CP70 cells.
Zylka and his colleagues stumbled upon the discovery by accident while studying topotecan, a topoisomerase-inhibiting drug that is used in chemotherapy.
Irinotecan and Topotecan are semisynthetic analogue of natural alkaloid Camptothecin ,and currently are the most widely used camptothecin analogs in clinical experiments that targets topoisomerase I enzyme.
has added topotecan hydrochlotide for injection, 4 mg (base)/vial, to its portfolio.
The North of England Cancer Drug Approvals Group has given the go-ahead to an oral treatment called Topotecan for patients with small cell lung cancer who have relapsed after receiving their initial treatment.